COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00333567
Recruitment Status : Completed
First Posted : June 5, 2006
Last Update Posted : December 13, 2007
Information provided by:

Brief Summary:
This study is designed to investigate the efficacy and safety of a single daily dose of 400 mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing pain associated with ambulatory arthroscopic knee surgery

Condition or disease Intervention/treatment Phase
Pain Drug: Lumiracoxib Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy of a Single Dose of Lumiracoxib 400 mg Given Pre-Emptively Versus Post-Operatively, in Reducing Pain Associated With Ambulatory Arthroscopic Knee Surgery
Study Start Date : August 2006

Primary Outcome Measures :
  1. Pain Intensity (PI) in the target knee after movement at the 2 h time-point

Secondary Outcome Measures :
  1. PI at 1, 2, 3, 4 and 24 h time-points while at rest
  2. PI at 1, 3, 4 and 24 h time-points after movement
  3. Time to first rescue medication intake
  4. Patient's global evaluation of response to study medication
  5. Safety and tolerability profile

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who need scheduled minor ambulatory arthroscopic knee surgery.

Exclusion Criteria:

  • Patients with any surgical or medical conditions which could place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirements of the study or completing the trial period.

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00333567

Layout table for location information
Nuernberg, Germany
Sponsors and Collaborators
Layout table for investigator information
Study Director: Novartis Pharma AG Novartis

Layout table for additonal information Identifier: NCT00333567    
Other Study ID Numbers: CCOX189A2427
First Posted: June 5, 2006    Key Record Dates
Last Update Posted: December 13, 2007
Last Verified: December 2007
Keywords provided by Novartis:
arthroscopic knee surgery
cyclooxygenase-2 inhibitors
Ambulatory arthroscopic knee surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents